Institutional Fund
Lynx1 Capital Management LP
Dorado, PRCIK 19104565 filings on record
Portfolio Value
$632.72M
Q1 2026
Holdings
23
Reported positions
New Buys
5
Opened this quarter
QoQ Change
+28.1%
from $494.00M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Stoke Therapeutics Inc24.5%
- Gh Research PLC23.9%
- Cullinan Therapeutics Inc20.1%
- Agios Pharmaceuticals Inc14.0%
- Denali Therapeutics Inc5.7%
- C4 Therapeutics Inc2.9%
- Other8.9%
Portfolio Holdings
23 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Stoke Therapeutics Inc | 4.76M | $155.11M | 24.5% | −641.0K | Reduced |
| 2 | Gh Research PLC | 10.76M | $151.33M | 23.9% | +356.7K | Added |
| 3 | Cullinan Therapeutics Inc | 8.96M | $127.37M | 20.1% | 0 | Held |
| 4 | Agios Pharmaceuticals Inc | 2.61M | $88.35M | 14.0% | +2.53M | Added |
| 5 | Denali Therapeutics Inc | 1.88M | $36.10M | 5.7% | +141.6K | Added |
| 6 | C4 Therapeutics Inc | 7.00M | $18.41M | 2.9% | −99.2K | Reduced |
| 7 | Korro Bio Inc | 1.54M | $17.41M | 2.8% | +860.4K | Added |
| 8 | Tscan Therapeutics Inc | 8.02M | $8.10M | 1.3% | 0 | Held |
| 9 | Xencor Inc | 536.4K | $6.47M | 1.0% | −169.2K | Reduced |
| 10 | Precision Biosciences Inc | 985.1K | $5.42M | 0.9% | −8.8K | Reduced |
13 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio